ReviewDermatology and therapy2026
Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric psoriasis is a chronic, immune-mediated inflammatory disease that frequently begins in childhood or adolescence. Beyond cutaneous involvement, it is associated with a wide spectrum of metabolic, psychological, and inflammatory comorbidities, as well as a marked impairment in health-related quality of life in both patients and their caregivers. This narrative review summarizes current evidence on comorbidities, treatment challenges, unmet needs, and future directions in pediatric psoriasis. Available data indicate an increased risk of overweight and obesity, the clustering of cardiometabolic risk factors, and a high prevalence of psychological and psychiatric comorbidities, including depression, anxiety, and suicidal ideation. Inflammatory comorbidities, particularly psoriatic arthritis, require early recognition to prevent irreversible complications. Therapeutic management of pediatric psoriasis has advanced in recent years with the approval of several biologic therapies supported by pediatric-specific clinical trials. Nevertheless, important challenges remain. These include limited access to biologics, age restrictions, off-label use of conventional systemic therapies, vaccination considerations, and scarcity of long-term safety data, particularly regarding growth, pubertal development, and cumulative drug exposure. Moreover, clear and regularly updated therapeutic algorithms for pediatric patients are still lacking. Despite increasing research activity and ongoing clinical trials, substantial unmet needs persist. These include delays in pediatric drug development, limited evidence beyond plaque psoriasis, insufficient evaluation of extracutaneous outcomes, and poor understanding of the long-term trajectory of comorbidities. Emerging data suggesting immunopathogenic differences between pediatric and adult psoriasis, together with ongoing biomarker research, may inform future personalized approaches. Addressing these gaps will be essential to optimize long-term, patient-centered care for children and adolescents with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.